The suggested BCR::ABL1 RT-qPCR quantification protocol [13] for CML patients relies on periodical molecular monitoring, wherein we look for expression levels that could indicate a therapeutical failure, taking to a TKI switch. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.